Mr. Moran has served as Chief Executive Officer since October 1, 2018. Prior to joining us, from 2015 to September 2018, Mr. Moran served as President of the Americas, ConvaTec Group Plc (LON: CTEC) (“ConvaTec”), an international medical products and technologies company, offering products and services in the areas of wound and skin care, ostomy care, continence and critical care and infusion devices. Prior to his employment at ConvaTec, Mr. Moran held roles in sales, marketing and general management over the course of eighteen years at Covidien plc (“Covidien”), an Irish headquartered global health care products company and manufacturer of medical devices and supplies. While at Covidien, until 2015, Mr. Moran served simultaneously as VP and General Manager of both the SharpSafety and Monitoring & Operating Room divisions. Following the 2015 acquisition of Covidien by Medtronic (NYSE:MDT), Mr. Moran was named the Global Vice President and General Manager of the Patient Care and Safety Division. Mr. Moran also served on the CEO Advisory Council for Advanced Medical Technology Association (AdvaMed), a medical device trade association. Mr. Moran earned a B.A. in Organizational Communication at The State University of New York at Geneseo. Mr. Moran was selected as a director because of his broad commercial experience and leadership in the medical technology sector.

Mr. Pomeranz has served as Chief Operating Officer since September 24, 2018. Prior to his tenure as our Chief Operating Officer, Mr. Pomeranz served as our Chief Executive Officer from December 2016 through September 2018, and as the Chief Executive Officer of Motus GI Medical Technologies Ltd., our wholly owned subsidiary, from 2014 through September 2018. Prior to joining Motus GI Medical Technologies Ltd., from 2008 to 2014, Mr. Pomeranz was the founding CEO of Svelte Medical Systems, a start-up company that is currently commercializing a unique drug eluting stent platform in the EU. From 2007 to 2008 Mr. Pomeranz was the Vice President of Research and Development at Prescient Medical, Inc. From 1998 to 2007, Mr. Pomeranz served as Vice President at Cordis, a Johnson & Johnson Company, where his responsibilities included developing new technologies, exploring new market opportunities and leading major restructuring efforts to create cross-functional global commercialization teams. Prior to that, Mr. Pomeranz held a number of senior leadership roles, including positions at Cardiac Pathways Corporations from 1991 to 1998, and Cardiovascular Imaging Systems from 1989 to 1991, both of which were acquired by Boston Scientific Corporation. Mr. Pomeranz earned a M.Sc. in biomedical engineering from the University of Miami. Mr. Pomeranz was selected as a director due to his history as a director of Motus GI Medical Technologies Ltd. and his business and leadership experience in the medical technology sector; his broad scientific background is also seen as an asset to us.

Mr. Taylor has served as our Chief Financial Officer since August 2017. Prior to joining us, Mr. Taylor served as the CFO and President of Angel Medical Systems from 2007 until 2017. Angel Medical Systems is a medical device company that develops and manufactures ischemia monitoring and alerting systems. While at Angel Medical Systems, Mr. Taylor supervised the operations of more than fifty (50) employees in the United States and Brazil, while also overseeing the financial planning and analysis activities, capital raise efforts, and implementation of capital and operating budgets.

From 2005 to 2007, Mr. Taylor was a Practice Leader for AC Lordi Consulting, where he oversaw staff providing CFO and Controller consulting services. Prior to that, Mr. Taylor was the CFO of Safe3w, Inc. from 2001 to 2005 until its acquisition by iPass, Inc. (NASDAQ: IPAS), where he led all accounting and finance functions, as well as the fundraising efforts and negotiated the sale of the company.

From 1999 to 2001, Mr. Taylor served as the Vice President of Finance and Administration of Abridge, Inc., where he developed and managed processes for budgeting, forecasting and cash management. Prior to that, Mr. Taylor was a Senior Finance Associate at Delta Air Lines (NYSE: DAL), from 1998 to 1999.

Mr. Taylor is a CFA Program Level II Candidate and earned a B.A. in Political Science and Economics at McGill University and his MBA in Finance at Northeastern University.

Mr. Hutchison has over 25 years of executive sales leadership and new market development experience in the medical device industry.

He most recently served as Vice President of U.S. Sales for Bio2 Medical where he was responsible for leading all commercial activities from FDA 510k clearance through national launch for market development technology for the prevention of pulmonary embolism. Prior to that, he served as Area Vice President of Sales for Medtronic GI Solutions (NYSE: MDT) where he led the Western Division of Medtronic’s GI business, managed the integration of two major acquisitions and led the growth of the organization from 33 territories and 4 regions to 135 territories and 18 regions. Previously, he served as Director of U.S. Sales for BÂRRX Medical, where he led the U.S. sales organization and drove commercialization of BÂRRX’s endoscopic treatment devices for Barrett’s Esophagus. Mr. Hutchison was an integral part of the BÂRRX acquisition team when it was purchased in 2011 by Coviden and later acquired by Medtronic. During that time, he oversaw the hiring of 50 professionals and grew the company’s domestic business by 20% over prior year, with 40% reduction in CMS reimbursement. Prior to BÂRRX, Mr. Hutchison spent 17 years at Boston Scientific (NYSE: BSX) in a variety of sales, sales management and market development roles in the endoscopy and cardiology divisions.

Mr. Hutchison holds a BS in Marketing from Bradley University and a MBA from the University of Phoenix.

Mr. Aldrich has significant experience in the Medical Device industry, having launched many advanced and disruptive products in both the US and international markets. He has a proven track record of commercial success in the GI space, specifically in leading marketing, operations and strategy functions.

Most recently, he served as Director of Marketing for Dutch Ophthalmic, where he was responsible for marketing and operations for their ophthalmic surgery portfolio of products.

Prior to that, Mr. Aldrich was Director of Marketing at Mauna Kea Technologies (EPA: MKEA), creator of the Cellvizio® system, a breakthrough imaging technology changing the way gastroenterologists diagnose and treat cancer and other diseases. He was responsible for developing and leading the company’s Marketing vision and strategy. Before being promoted to Director of Marketing, Mr. Aldrich served as the Head of Product Management, where he led customer-focused innovation and market expansion.

Before joining Mauna Kea Technologies, Scott worked for Pentax Medical, a division of HOYA Group, delivering leading-edge endo-imaging solutions to gastroenterologists, pulmonologist and urologists. During his tenure at Pentax Medical, Mr. Aldrich held various roles in sales, marketing and product management.

Mr. Aldrich earned his BA in Psychology from Amherst College.

Mrs. Ram brings to Motus GI over 17 years of financial and operational leadership of international technology and medical device companies. Involved in strategic decisions and processes through the company’s various life cycles from startups to well established public companies. Highly experienced in establishing the necessary process in accordance with company needs and business phase. Prior to joining Motus GI in April 2018, Mrs. Ram served as the Director of Finance, supply chain, and site manager at EndoChoice, managing EndoChoice Israeli site finance, supply chain, and IT departments. Earlier, she served as Global Director Operation Controller at Given Imaging, responsible for all financial aspects of company global operations and R&D activities. Mrs. Ram earned her B.A. in Finance and Sociology at ‘Bar Ilan’ University and M.A. in Actuary – Haifa University.